Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma. (AKI CAR)

Civil Hospices of Lyon

Status: Active, not recruiting

Conditions: Infusion of CD19 CAR T Cell; B Cell Lymphoma; Acute Kidney Injury (AKI)

Treatments: Biological: Incidence of acute kidney injury; Other: Long term evolution after treatment by CAR-T cells; Other: Describe risk factors in AKI occurrence.; Other: Focus on patient with chronic kidney disease at baseline

Study type: Observational

Funder types: Other

Identifiers

NCT07101913

24-5297

Details and patient eligibility

About

The investigators want to describe the incidence of AKI after CAR-T cells therapy in B-cell lymphoma. With the aim of highlight risk factors in AKI occurrence. Then, look at outcomes in the subgroup with chronic kidney disease at baseline. Finally, the investigators will examine long term evolution of kidney function.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients followed in haematology center in "Hospices civils de Lyon"
• For a B-cell lymphoma
• Treated by anti-CD19 CAR-T cells

Exclusion criteria

• Less than 18 years old
• Patients with legal protection measure
• CAR-T cells therapy for another disease : leukemia, autoimmune disease...

Trial design

300 participants in 1 patient group

CAR-T cells treatment

Description:

All patients followed in haematology center in "Hospices civils de Lyon" for a B-cell lymphoma and treated by anti-CD19 CAR-T cells.

Treatment:

Other: Focus on patient with chronic kidney disease at baseline

Other: Long term evolution after treatment by CAR-T cells

Other: Describe risk factors in AKI occurrence.

Biological: Incidence of acute kidney injury